Mantle Cell Lymphoma Market
Oct 14, 2025
FDA Approves Boehringer’s JASCAYD as First New IPF Therapy in Over a Decade; Denali Therapeutics’ Tividenofusp Alfa BLA Review for Hunter Syndrome Extended by FDA; Bicara’s Ficerafusp Alfa Earns FDA Breakthrough Tag for 1L HPV-Negative Head & Neck Cancer; BeOne Medicines’ Sonrotoclax Granted FDA Breakthrough Designation for Cancer Treatment; FDA Clears LIBTAYO for Adjuvant Use in Cutaneous Squamous Cell Carcinoma
FDA Approves Boehringer’s JASCAYD as First New IPF Therapy in Over a Decade Boehringer Ingelheim’s JASCAYD (nerandomilast) has received FDA approval as an oral treatment for adults with idiopathic pulmonary fibrosis (IPF), marking the first new therapy for the condition in over a decade. JASCAYD is the first and...
Read More...
Dec 15, 2023
Breaking Ground: Ibrutinib and Venetoclax Synergy Delivers Significant Progression-Free Survival Boost in Relapsed/Refractory Mantle Cell Lymphoma
Date of Abstract presentation12th December 2023IndicationsMantle Cell Lymphoma (MCL)Abstract NumberLBA-2Abstract typeOral Ibrutinib, an oral BTK inhibitor, holds approval in numerous countries for the treatment of R/R MCL. Similarly, venetoclax, an oral BCL2 inhibitor, has gained approval in multiple countries f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
